Fulgent Genetics Inc (OQ:FLGT)

Business Focus: Medical & Diagnostic Laboratories

Sector:  Healthcare Industry:  Healthcare Facilities & Services
See Regulatory Filings on SEC
Company Contact
Address: 4399 SANTA ANITA AVE
Tel: 1-415-2174964
Website: https://www.fulgentgenetics.com
IR: See website
Key People
Ming Hsieh
Chairman of the Board, Chief Executive Officer
Jian Xie
President, Chief Operating Officer
Paul Kim
Chief Financial Officer
Hanlin Gao
Chief Scientific Officer, Laboratory Director
Business Overview
Fulgent Genetics, Inc. is a technology-based genetic company with a laboratory services business and a therapeutic development business. The Company's laboratory services business includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile (PK) profile of new and existing cancer drugs. Its technology platform for its laboratory services business includes gene probes, data suppression and comparison algorithms, learning software, and laboratory information management systems. The platform provides a test menu, the ability to rapidly develop and launch new tests and customizable test offerings. The Company also offers next-generation sequencing (NGS) services.
Financial Overview
For the three months ended 31 March 2024, Fulgent Genetics Inc revenues decreased 3% to $64.5M. Net loss decreased 12% to $13.5M. Revenues reflect Institutional segment decrease of 13% to $30M, United States segment decrease of 7% to $57.9M. Lower net loss reflects Interest income and other income increase from $3.8M to $7.6M (income), General and administrative decrease of 10% to $16.9M (expense).
Employees: 1,184 as of Feb 15, 2024
Reporting Currency: U.S. Dollars
Enterprise value: $267.14M as of Mar 31, 2024
Annual revenue (TTM): $287.53M as of Mar 31, 2024
EBITDA (TTM): -$46.28M as of Mar 31, 2024
Net annual income (TTM): -$165.95M as of Mar 31, 2024
Free cash flow (TTM): $17.95M as of Mar 31, 2024
Net Debt Last Fiscal Year: N/A
Shares outstanding: 29,924,288 as of May 1, 2024
Index Membership: S&P 600 Small Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.